AcelRx Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary

Talphera

10/08/2023 22:59

* AcelRx Pharmaceuticals Inc  ACRX.OQ  reported a quarterly
adjusted loss of 40 cents​​ per share for the quarter ended in
June. The lone analyst forecast for the quarter was for a loss
of 53 cents per share.
    * Revenue fell 55.6% to $253.00 thousand from a year ago;
analysts
expected $75.00 thousand. 
    * AcelRx Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 40 cents​.
    * The mean earnings estimate of analysts had fallen by
about 5% in
the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * AcelRx Pharmaceuticals Inc shares had fallen by 14.4% this
quarter and lost 58.0% so far this year.
    * The company reported a quarterly loss of $4.37 million.
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 10 at 09:59 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.53          -0.40          Beat
 Mar. 31 2023      -1.39          -0.75          Beat
 Dec. 31 2022      -0.51          -1.00          Missed
 Sep. 30 2022      -1.20          -0.94          Beat